Unique mode of action to destroy MCTs1
Tigilanol tiglate is administered as an injection directly into the tumour.
In canine MCTs, tigilanol tiglate canine has been shown to:1
1
Elicit a rapid and localised inflammatory response, causing swelling and erythema extending to the tumour margins and immediate surrounds that generally resolves within 48 to 96 hours
2
Induce tumour cell death
3
Cause loss of integrity of the tumour vasculature via activation of specific isoforms of protein kinase C (PKC)
These processes lead to haemorrhagic necrosis and necrotic destruction of the tumour mass within 4 to 7 days of treatment.1
Video explaining mode of action
Witness tigilanol tiglate in action:
12-year old male crossbreed
Day 0
Pre-treatment
8 Hours
Swelling and vascular changes evident
Day 4
Tumour necrosis
Day 7
Tumour destroyed
Granulation of tumour site
Day 28
Tumour site healing
Day 42
Tumour site healed
5-year old male crossbreed
Day 0
Pre-treatment
Day 1
Tumour necrosis evident
Day 7
Starting to granulate
Day 14
Tumour site healing
Day 28
Tumour site healed
